Duchenne Muscular Dystrophy News
Top stories
Sarepta Therapeutics and Roche have announced positive results from the Part 2 of the EMBARK study, which focused on the treatment ELEVIDYS for Duchenne Muscular Dystrophy (DMD). Sarepta reported sustained benefits and disease stabilization in ambulatory individuals with DMD following treatment with ELEVIDYS. Roche also highlighted the significant sustained benefits of the drug in the same patient group. Additionally, Veru announced positive topline data from its Phase 2b QUALITY clinical study, revealing that its investigational drug, enobosarm, helped preserve lean mass in patients taking Wegovy (semaglutide) for weight reduction. The study indicated that patients on enobosarm lost 71% less lean mass compared to those receiving Wegovy alone, with a statistically significant p-value of 0.002.